Moleculin BiotechMBRX +3.95%30 Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus rates MBRX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 839 Biotechnology companies, Moleculin Biotech ranks worse than 119189.39% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Moleculin Biotech's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Moleculin Biotech's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.00 Mil.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Moleculin Biotech Receivables Turnover Related Terms
Moleculin Biotech Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Moleculin Biotech's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MBRX vs JAGX, BCDA, AKTX: Receivables Turnover Comparison
For the Biotechnology subindustry, Moleculin Biotech's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moleculin Biotech Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Moleculin Biotech's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Moleculin Biotech's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moleculin Biotech (MBRX) has a Receivables Turnover of 0.00 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Moleculin Biotech and its competitors. According to the industry distribution chart, Moleculin Biotech ranks #999999 out of 839 companies in the Biotechnology industry.
Is Moleculin Biotech's Receivables Turnover too high?
Moleculin Biotech's current Receivables Turnover is 0.00. Based on the distribution chart, Moleculin Biotech ranks #999999 out of 839 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Moleculin Biotech has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Moleculin Biotech's Receivables Turnover compare to JAGX and BCDA?
According to the Biotechnology industry distribution chart, Moleculin Biotech ranks #999999 out of 839 companies for Receivables Turnover. This places Moleculin Biotech in the lower half of its industry. The industry median Receivables Turnover is 5.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 839 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Moleculin Biotech and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moleculin Biotech's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moleculin Biotech stock overvalued right now?
Moleculin Biotech (MBRX) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Moleculin Biotech's overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Moleculin Biotech (MBRX), the current Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
30GF Score
Get the complete analysis for MBRX
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBRX has been successfully added to your 
